Form 4: Cellectar Biosciences CEO Acquires 900,000 Stock Options
SEC Form 4 Filing
James V. Caruso, President and CEO of Cellectar Biosciences, Inc., was granted options to purchase 900,000 shares of common stock on February 14, 2025.
Summary
- James V. Caruso, the President and CEO of Cellectar Biosciences, Inc., received stock options on February 14, 2025.
- The options grant him the right to purchase 900,000 shares of Cellectar's common stock at an exercise price of $0.29 per share.
- The options vest over a three-year period, with one-third vesting on February 14, 2026, and the remaining portion vesting in 24 equal monthly installments thereafter.
- The options expire on February 14, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain any specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The size of the grant and the vesting schedule are typical for a company of Cellectar's size and stage of development.
- Comparing Cellectar's executive compensation structure to peers like Geron Corporation or Northwest Biotherapeutics would provide a more detailed benchmark.
Stakeholder Impact
- Shareholders may view the option grant as a positive incentive for the CEO.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of the stock option grant. |
| 02/14/2026 | First vesting date for 1/3 of the options. |
| 02/14/2035 | Expiration date of the stock options. |
| 02/18/2025 | Date of the Form 4 filing. |
Keywords
stock options, Cellectar Biosciences, CLRB, James V. Caruso, CEO, beneficial ownership, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.